What’s new

• Commercial operations began June 29 at a new 200 KLPD corn/grain-based ethanol distillery at Sameerwadi.
• The unit adds to the existing 600 KLPD sugar-based plant, enabling dual-feedstock flexibility.
• Investment of ₹130 crore funded through internal accruals and debt.

Why it matters

Godavari's existing distillery ran at just 41% utilisation, hamstrung by sugar-cane seasonality. Grain-based ethanol decouples output from cane availability and aligns with India's rising ethanol blending mandates. For a micro-cap with ₹1,441 crore market cap, ₹130 crore is a material bet, one that could lift capacity utilisation and revenue if demand holds.

What we’re watching

• Utilisation ramp of the new 200 KLPD unit over the next two quarters.
• Margins on grain ethanol compared to molasses-based production.
• Any further updates on the company's patent or pharma diversification.

The full read

Godavari Biorefineries fired up a new 200 KLPD grain-based ethanol distillery on June 29, a ₹130 crore bet on feedstock flexibility. The plant at Sameerwadi runs on corn and grain, a deliberate break from its existing 600 KLPD sugar-based line that had been limping at 41% utilisation. The investment, roughly 9% of Godavari's ₹1,441 crore market cap, gives the micro-cap a second procurement channel and a hedge against cane supply shocks. India's ethanol blending mandate is the pull, but the real story is the push: a sugar stock that can now run its stills even when cane runs thin. Execution pace and margins on grain ethanol will determine the payoff.

Primary source: BSE · NSE

What’s new

• Godavari Biorefineries granted Japanese patent for cancer treatment compound.
• Compound 5-hydroxy-1,4-naphthalenedione shows activity against breast and prostate cancer stem cells.
• No plans to commercialise the patented technology have been announced.

Why it matters

For a micro-cap sugar and bio-based chemicals producer, a pharma patent is an unexpected addition to its IP. But with no path to market and zero near-term revenue, the value is optional, not tangible. The development adds optional value but clearly remains non-core.

What we’re watching

• Any licensing or partnership announcements for the patented compound.
• Whether Godavari files further patents in the oncology space.
• Impact on R&D spending and the narrative around a potential pharma pivot.

The full read

Godavari Biorefineries, a ₹1,535 cr sugar-and-ethanol producer, was granted Japanese patent 7869786 for a compound targeting breast and prostate cancer stem cells. The patent covers 5-hydroxy-1,4-naphthalenedione, filed in 2021 and registered this May. Zero near-term earnings impact. No commercialization plan has been disclosed, and the company's core remains biorefining — making this an unexpected but strictly optional IP asset.

Primary source: BSE · NSE

What’s new

• FY26 net profit of ₹3.5 cr marks a turnaround from the previous year's ₹23.4 cr loss.
• Record sugarcane crushing of 2.5 million tonnes drove a 15.8% increase in EBITDA.
• A new 60 million litre grain-based distillery begins trial runs in May-June 2026.

Why it matters

The 32% reduction in finance costs is the primary driver behind this profit swing. By diversifying into grain-based feedstock, the company is attempting to insulate its margins from the volatility of sugarcane supply.

What we’re watching

• Whether the new grain-based distillery hits its 60 million litre capacity target.
• Market penetration of bio-based chemicals as the specialty mix reaches 61%.
• Sustainability of the earnings as the company scales its third feedstock option.

The full read

Godavari Biorefineries ended its loss-making streak. After posting a ₹23.4 crore loss in the prior year, the company reported a consolidated net profit of ₹3.5 crore for FY26. Revenue growth remained modest at 6% to reach ₹2,000.2 crore. The bottom line benefited from a 32% reduction in finance costs and a record 2.5 million tonnes of sugarcane crushed. The company is now betting on its bio-based chemicals segment, where the specialty mix has climbed to 61%. Management expects this momentum to carry into the current quarter. To stabilize earnings, a new grain-based distillery with 60 million litres of annual capacity is slated for trial runs in May-June 2026. This third feedstock option is an attempt to move away from the supply volatility that has historically hampered the business. The next test is whether the new distillery can deliver the expected earnings stability.

Primary source: BSE · NSE

What’s new

• Revenue grew 6% to ₹1,987.94 cr, supported by record sugarcane crushing.
• Standalone Q4 net profit reached ₹52.88 cr.
• Exceptional costs of ₹31.14 cr related to labour and harvest charges weighed on the bottom line.

Why it matters

The shift to profitability confirms an operational recovery in its sugar and distillery segments. While annual margins remain thin relative to its ₹1,604 cr market cap, the swing from a prior year loss removes a key performance overhang.

What we’re watching

• Sustainability of ethanol margins heading into FY27.
• Management plans for managing the high exceptional costs seen this year.
• Impact of continued sugarcane crushing volumes on cash flow.

The full read

Godavari Biorefineries finally navigated a recovery year, posting a consolidated net profit of ₹3.53 crore for FY26. This marks a significant swing from the ₹23.41 crore loss recorded in the previous year. Revenue improved by 6% to ₹1,987.94 crore, as record crushing volumes in the distillery and sugar segments pushed the company back into the black.

Standalone performance in the final quarter provided ₹52.88 crore in net profit. This momentum persisted despite absorbing ₹31.14 crore in one-time exceptional expenses linked to new labour codes and elevated harvest charges. Although the bottom line remains modest compared to its ₹1,604 crore market valuation, the transition to profitability confirms that the core operational recovery is real. Managing Director Samir Somaiya will continue to lead this effort for another three-year term.

It is a start.

Primary source: BSE · NSE